Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.

Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.

There is no current approved therapy for the ultimately lethal neuro- and cardio-degenerative disease Friedreich's ataxia (FA). Finding minimally-invasive molecular biomarkers of disease progression and drug effect could support smaller, shorter clinical trials. Since we and others have noted a...

Descripció completa

Dades bibliogràfiques
Autors principals:	Genki Hayashi, Gino Cortopassi
Format:	Article
Idioma:	English
Publicat:	Public Library of Science (PLoS) 2016-01-01
Col·lecció:	PLoS ONE
Accés en línia:	http://europepmc.org/articles/PMC4831832?pdf=render

Ítems similars

Sexual dimorphism in a mouse model of Friedreich’s ataxia with severe cardiomyopathy
per: Lili Salinas, et al.
Publicat: (2024-10-01)

Potential biomarker identification for Friedreich's ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion.
per: Marissa Z McMackin, et al.
Publicat: (2019-01-01)

Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich's Ataxia.
per: Mittal Jasoliya, et al.
Publicat: (2019-01-01)

Genetics and Friedreich Ataxia
per: J Gordon Millichap
Publicat: (2002-06-01)

Genetics of Friedreich Ataxia
per: J Gordon Millichap
Publicat: (1997-06-01)

Friedreich’s Ataxia: A Neuronal Point of View on the Oxidative Stress Hypothesis
per: Barbara Carletti, et al.
Publicat: (2014-09-01)

Molecular Defects in Friedreich’s Ataxia: Convergence of Oxidative Stress and Cytoskeletal Abnormalities
per: Frances M. Smith, et al.
Publicat: (2020-11-01)

Late-Onset Friedreich’s Ataxia
per: J Gordon Millichap
Publicat: (1993-08-01)

Friedreich’s Ataxia with Retained Reflexes
per: J Gordon Millichap
Publicat: (1995-04-01)

Friedreich's Ataxia and Glucose Metabolism
per: J Gordon Millichap
Publicat: (1988-08-01)

5-Hydroxytryptophan in Friedreich’s Ataxia
per: J Gordon Millichap
Publicat: (1995-06-01)

Iron Storage in Friedreich’s Ataxia
per: J Gordon Millichap
Publicat: (1999-08-01)

Tissue Iron in Friedreich Ataxia
per: Arnulf H Koeppen
Publicat: (2024-01-01)

Respiratory Function in Friedreich’s Ataxia
per: Elena Vinante, et al.
Publicat: (2022-08-01)

The pathogenesis of cardiomyopathy in Friedreich ataxia.
per: Arnulf H Koeppen, et al.
Publicat: (2015-01-01)

Is Friedreich ataxia an epigenetic disorder?
per: Kumari Daman, et al.
Publicat: (2012-01-01)

Epigenetic modification of the frataxin gene for the treatment of Friedreich’s ataxia
per: Vilema Enriquez, MG
Publicat: (2018)

Friedreich ataxia in a family from Mali, West Africa/Friedreich ataxia in a Malian family
per: Cheick A. K. Cissé, et al.
Publicat: (2021-05-01)

Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich’s Ataxia
per: Anusha Sivakumar, et al.
Publicat: (2022-05-01)

Antioxidant Therapies and Oxidative Stress in Friedreich’s Ataxia: The Right Path or Just a Diversion?
per: Laura R. Rodríguez, et al.
Publicat: (2020-07-01)

Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia.
per: Vincent Paupe, et al.
Publicat: (2009-01-01)

Exploring neuropsychiatric symptoms in Friedreich ataxia
per: Simona Karamazovova, et al.
Publicat: (2024-11-01)

Friedreichs ataxia in a diabetic patient
per: Inna Igorevna Klefortova, et al.
Publicat: (2010-06-01)

Friedreich's Ataxia – A Clinical Diagnosis
per: Md. Fekarul Islam, et al.
Publicat: (2015-01-01)

Clinical and Genetic Diagnosis of Friedreich’s Ataxia
per: J Gordon Millichap
Publicat: (1998-05-01)

Emerging antioxidant therapies in Friedreich’s ataxia
per: Fred Jonathan Edzeamey, et al.
Publicat: (2024-02-01)

An Overview of the Ferroptosis Hallmarks in Friedreich’s Ataxia
per: Riccardo Turchi, et al.
Publicat: (2020-10-01)

Perspectives on current models of Friedreich’s ataxia
per: Simge Kelekçi, et al.
Publicat: (2022-08-01)

Anaesthesia for a patient with Friedreich′s ataxia
per: Ilango Ganesan
Publicat: (2011-01-01)

Otoneurological Abnormalities in Patients with Friedreich's Ataxia
per: Bianca Simone Zeigelboim, et al.
Publicat: (2017-01-01)

Epigenetic-based therapies for Friedreich ataxia
per: Chiranjeevi eSandi, et al.
Publicat: (2014-06-01)

Predictors of loss of ambulation in Friedreich's ataxia
per: Christian Rummey, et al.
Publicat: (2020-01-01)

Hepatic mitochondrial dysfunction in Friedreich Ataxia
per: Stüwe Sven H, et al.
Publicat: (2011-11-01)

Prediction of the disease course in Friedreich ataxia
per: Christian Hohenfeld, et al.
Publicat: (2022-11-01)

Friedreich’s Ataxia-A Case Report
per: Tahreem Muntaha, et al.
Publicat: (2018-11-01)

Friedreich ataxia- pathogenesis and implications for therapies
per: Martin B. Delatycki, et al.
Publicat: (2019-12-01)

At-home wearable-based monitoring predicts clinical measures and biological biomarkers of disease severity in Friedreich’s Ataxia
per: Ram Kinker Mishra, et al.
Publicat: (2024-10-01)

Perspectives of the Friedreich ataxia community on gene therapy clinical trials
per: Shandra J. Trantham, et al.
Publicat: (2024-03-01)

Estrogen prevents oxidative damage to the mitochondria in Friedreich's ataxia skin fibroblasts.
per: Timothy E Richardson, et al.
Publicat: (2012-01-01)

Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich’s Ataxia Models
per: Rosella Abeti, et al.
Publicat: (2018-07-01)